Carotid Atherosclerosis in Patients with Atrial Fibrillation

  • Zhaojia Wang
  • Panagiotis Korantzopoulos
  • Tong LiuEmail author
Evidence-Based Medicine, Clinical Trials and Their Interpretations (L. Roever, Section Editor)


Purpose of Review

This review aims to explore the relationship between AF and carotid atherosclerosis, and the impact on the outcomes of cardiovascular and cerebrovascular events. Also, our aim is to critically review current knowledge and delineate future directions for effective treatment or prevention as well as strategies for improvement of the quality of life and survival.

Recent Findings

Atrial fibrillation (AF) is the most common arrhythmia, increasing the risk of stroke and cardiovascular morbidity and mortality representing a significant worldwide public health problem. On the other hand, carotid artery atherosclerosis can also significantly increase the risk of stroke, transient ischemic attack (TIA), and death.


Firstly, we report epidemiological data on AF patients in different countries and regions having carotid artery abnormalities such as carotid artery plaque formation, atherosclerotic, and even stenosis. Despite geographical variations, these abnormalities were more frequent in AF patients and correlated with the duration of AF and the value of CHA2DS2-VASc score. Moreover, it is evident that AF patients with carotid artery abnormalities have significantly increased risk of adverse outcomes from the heart and brain. According to the CHA(2)DS2 (-VASc) score, AF patients are managed with anticoagulation therapy. Reviewing existing data on the treatment for stroke prevention in patients with AF, carotid artery disease, or both, we found that antiplatelet therapy could be combined with anticoagulant therapy appropriately in certain circumstances. In addition, some emerging technologies, such as the percutaneous permanent carotid filter, may be used safely and effectively to prevent the occurrence of stroke in patients both with AF and carotid artery atherosclerosis.


Atrial Fibrillation Carotid Atherosclerosis Anticoagulant Therapy Antiplatelet Therapy 


Funding Information

This work was supported by grants (81970270, 30900618, 81270245, and 81570298 to T.L.) from the National Natural Science Foundation of China and Tianjin Natural Science Foundation (16JCZDJC34900 to T.L.).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Chen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e623–e44. Scholar
  2. 2.
    Basili S, Loffredo L, Pastori D, Proietti M, Farcomeni A, Vestri AR, et al. Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. Int J Cardiol. 2017;231:143–9. Scholar
  3. 3.
    Proietti M, Calvieri C, Malatino L, Signorelli S, Corazza GR, Perticone F, et al. Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. Atherosclerosis. 2015;238(2):350–5. Scholar
  4. 4.
    Becattini C, Dentali F, Camporese G, Sembolini A, Rancan E, Tonello C, et al. Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis. 2018;271:177–81. Scholar
  5. 5.
    Boriani G, Pettorelli D. Atrial fibrillation burden and atrial fibrillation type: clinical significance and impact on the risk of stroke and decision making for long-term anticoagulation. Vascul Pharmacol. 2016;83:26–35. Scholar
  6. 6.
    Reddy VY, Neuzil P, de Potter T, van der Heyden J, Tromp SC, Rensing B, et al. A percutaneous permanent carotid filter for stroke prevention in atrial fibrillation: the CAPTURE Trial. J Am Coll Cardiol. 2019. This report may provide a new strategy for preventing stroke in patients with atrial fibrillation who are not advised to take oral anticoagulants.CrossRefGoogle Scholar
  7. 7.
    Bekwelem W, Jensen PN, Norby FL, Soliman EZ, Agarwal SK, Lip GY, et al. Carotid atherosclerosis and stroke in atrial fibrillation: the atherosclerosis risk in communities study. Stroke. 2016;47(6):1643–6. Scholar
  8. 8.
    Alderman H, Behrman JR, Glewwe P, Fernald L, Walker S. Evidence of impact of interventions on growth and development during early and middle childhood. In: rd, Bundy DAP, Silva N, Horton S, Jamison DT, Patton GC, editors. Child and adolescent health and development. Washington (DC): 2017.Google Scholar
  9. 9.
    Chen LY, Foo DC, Wong RC, Seow SC, Gong L, Benditt DG, et al. Increased carotid intima-media thickness and arterial stiffness are associated with lone atrial fibrillation. Int J Cardiol. 2013;168(3):3132–4. Scholar
  10. 10.
    Willeit K, Kiechl S. Atherosclerosis and atrial fibrillation--two closely intertwined diseases. Atherosclerosis. 2014;233(2):679–81. Scholar
  11. 11.
    Cao JJ, Thach C, Manolio TA, Psaty BM, Kuller LH, Chaves PH, et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation. 2003;108(2):166–70. Scholar
  12. 12.
    Violi F, Daví G, Hiatt W, et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy, J. Am. Coll. Cardiol. 62 (2013) 2255–2256.CrossRefGoogle Scholar
  13. 13.
    Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701. Scholar
  14. 14.
    Chen LY, Leening MJ, Norby FL, Roetker NS, Hofman A, Franco OH, et al. Carotid intima-media thickness and arterial stiffness and the risk of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) Study, Multi-Ethnic Study of Atherosclerosis (MESA), and the Rotterdam Study. J Am Heart Assoc. 2016;5(5).
  15. 15.
    Shang L, Zhao Y, Shao M, Sun H, Feng M, Li Y, et al. The association of CHA2DS2-VASc score and carotid plaque in patients with non-valvular atrial fibrillation. PLoS One. 2019;14(2):e0210945. Scholar
  16. 16.
    Gu Y, Feng L, Xu Y, Zhao Y. Co-prevalence of carotid stenosis and coronary artery disease in Chinese patients with paroxysmal atrial fibrillation. J Int Med Res. 2014;42(6):1294–300. Scholar
  17. 17.
    Akanksha WG, Paramdeep K, Gagandeep S, Rajinder B, Birinder SP, Monika S, et al. Clinical features, risk factors, and short-term outcome of ischemic stroke, in patients with atrial fibrillation: data from a population-based study. Ann Indian Acad Neurol. 2017;20(3):289–93. Scholar
  18. 18.
    Yang PS, Pak HN, Park DH, Yoo J, Kim TH, Uhm JS, et al. Non-cardioembolic risk factors in atrial fibrillation-associated ischemic stroke. PLoS One. 2018;13(7):e0201062. Scholar
  19. 19.
    Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2002;13(1):16–20. Scholar
  20. 20.
    Lin LY, Yang LW, Shang YY, Li YH, Zhong M, Zhang W, et al. Role of the CHADS2 score in the evaluation of carotid atherosclerosis in patients with atrial fibrillation undergoing carotid artery ultrasonography. Biomed Res Int. 2018;2018:4074286. This article showed that the CHADS 2 score assessed carotid atherosclerosis in patients with atrial fibrillation undergoing carotid ultrasound. And they found the CHADS 2 score may be used effectively to predict the extent of carotid atherosclerosis in AF patients and carotid atherosclerosis degree relied on the duration of AF.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;70(2):427–51. Scholar
  22. 22.
    Adamsson Eryd S, Ostling G, Rosvall M, Persson M, Smith JG, Melander O, et al. Carotid intima-media thickness is associated with incidence of hospitalized atrial fibrillation. Atherosclerosis. 2014;233(2):673–8. Scholar
  23. 23.
    Willeit K, Pechlaner R, Egger G, Weger S, Oberhollenzer M, Willeit J, et al. Carotid atherosclerosis and incident atrial fibrillation. Arterioscler Thromb Vasc Biol. 2013;33(11):2660–5. Scholar
  24. 24.
    None. Corrigendum to: 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;50(5):e1–e88.Google Scholar
  25. 25.
    Dragunow M, Faull RLM. Neuroprotective effects of adenosine. Trends Pharmacol Sci. 1988;9(6):193–4.CrossRefGoogle Scholar
  26. 26.
    Feigin VL, Norrving B, Mensah GA. Global burden of stroke. Circ Res. 2017;120(3):439–48. Scholar
  27. 27.
    Cheng SF, Brown MM, Simister RJ, Richards T. Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke. Br J Surg. 2019;106(7):872–8. Scholar
  28. 28.
    Kochar A, Hellkamp AS, Lokhnygina Y, Jones WS, Becker RC, Berkowitz SD, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: insights from the ROCKET AF trial. Clin Cardiol. 2018;41(1):39–45. Scholar
  29. 29.
    Bunch TJ, Bair TL, Crandall BG, Cutler MJ, Day JD, Graves KG, et al. Stroke and dementia risk in patients with and without atrial fibrillation and carotid arterial disease. Heart Rhythm. 2019.
  30. 30.
    Lehtola H, Airaksinen KEJ, Hartikainen P, Hartikainen JEK, Palomaki A, Nuotio I, et al. Stroke recurrence in patients with atrial fibrillation: concomitant carotid artery stenosis doubles the risk. Eur J Neurol. 2017;24(5):719–25. Scholar
  31. 31.
    Zhou X, Cao K, Kou S, Qu S, Li H, Yu Y, et al. Usefulness of CHADS2 score for prognostic stratification of patients with coronary artery disease: a systematic review and meta-analysis of cohort studies. Int J Cardiol. 2017;228:906–11. Scholar
  32. 32.
    Li J, Liu X, Xiang Y, Ding X, Wang T, Liu Y, et al. Alpha-2-macroglobulin and heparin cofactor II and the vulnerability of carotid atherosclerotic plaques: an iTRAQ-based analysis. Biochem Biophys Res Commun. 2017;483(3):964–71. Scholar
  33. 33.
    Falsetti L, Viticchi G, Buratti L, Grigioni F, Capucci A, Silvestrini M. Interactions between atrial fibrillation, cardiovascular risk factors, and ApoE genotype in promoting cognitive decline in patients with Alzheimer’s disease: a prospective cohort study. J Alzheimers Dis. 2018;62(2):713–25. Scholar
  34. 34.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. Scholar
  35. 35.
    Dos Santos AP, Girotto M, Levin Y. Simulations of polyelectrolyte adsorption to a dielectric like-charged surface. J Phys Chem B. 2016;120(39):10387–93. Scholar
  36. 36.
    Pastori D, Eikelboom JW, Anand SS, Patel MR, Tanguay JF, Ricco JB, et al. Management of patients with asymptomatic and symptomatic carotid artery disease: update on anti-thrombotic therapy. Thromb Haemost. 2019;119(4):576–85. Scholar
  37. 37.
    Jolobe OMP. Mitigation of stroke risk in nonvalvular atrial fibrillation patients with high-grade carotid artery stenosis. Am J Med Sci. 2018;356(6):578–9. Scholar
  38. 38.
    Khattak F, Alam MB, Paul TK, Rijal S, Wazir S, Lavie CJ, et al. Antithrombotic therapy in nonvalvular atrial fibrillation: consensus and challenges. Am J Med Sci. 2018;355(5):467–76. Scholar
  39. 39.
    Hart RG, Pearce LA, Miller VT, Anderson DC, Rothrock JF, Albers GW, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10(1):39–43. Scholar
  40. 40.
    Katsi V, Georgiopoulos G, Skafida A, Oikonomou D, Klettas D, Vemmos K, et al. Noncardioembolic stroke in patients with atrial fibrillation. Angiology, This is one of the most recent articles showing differential efficacy of antithrombotic treatment strategies in non-CE ischemic syndromes with AF. 2019;70(4):299–304. Scholar
  41. 41.
    Kim YD, Cha MJ, Kim J, Lee DH, Lee HS, Nam CM, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke. 2011;42(4):930–4. Scholar
  42. 42.
    Duerschmied D, Brachmann J, Darius H, Frey N, Katus HA, Rottbauer W, et al. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Clin Res Cardiol. 2018;107(7):533–8. Scholar
  43. 43.
    •• Kim AS, Easton JD. New opportunities to optimize antithrombotic therapy for secondary stroke prevention. Int J Stroke. 2019;14(3):220–2. This is one of the most recent reviews of prevention of optimize antithrombotic therapy for stroke.CrossRefPubMedGoogle Scholar
  44. 44.
    The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet. 1997;349(9065):1569–81.Google Scholar
  45. 45.
    CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet. 1997;349(9066):1641–9.Google Scholar
  46. 46.
    Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. JAMA. 2016;316(1):70–8. Scholar
  47. 47.
    Hwang YS, Lin KK, Lee JS, Chang SH, Chen KJ, Lai CC, et al. Intravitreal loading injection of ganciclovir with or without adjunctive oral valganciclovir for cytomegalovirus anterior uveitis. Graefes Arch Clin Exp Ophthalmol. 2010;248(2):263–9. Scholar
  48. 48.
    Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16(4):301–10. Scholar
  49. 49.
    Hankey GJ. Stroke Lancet. 2017;389(10069):641–54. Scholar
  50. 50.
    Huang KY, Huang PJ, Ku FM, Lin R, Alderete JF, Tang P. Comparative transcriptomic and proteomic analyses of Trichomonas vaginalis following adherence to fibronectin. Infect Immun. 2012;80(11):3900–11. Scholar
  51. 51.
    Heo SH, Yoon KW, Woo SY, Park YJ, Kim YW, Kim KH, et al. Editor’s choice - comparison of early outcomes and restenosis rate between carotid endarterectomy and carotid artery stenting using propensity score matching analysis. Eur J Vasc Endovasc Surg. 2017;54(5):573–8. This is one of the most recent matching analyses to compare the early outcomes and restenosis rate between carotid endarterectomy and carotid artery stenting using propensity score.CrossRefPubMedGoogle Scholar
  52. 52.
    Bonati LH, Dobson J, Featherstone RL, Ederle J, van der Worp HB, de Borst GJ, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet. 2015;385(9967):529–38. Scholar
  53. 53.
    Forlivesi S, Pancheri E, Moretto G, Bovi P, Cappellari M. Early secondary prevention after initially ineffective revascularization treatments for acute ischemic stroke due to tandem occlusion. Blood Coagul Fibrinolysis. 2017;28(6):493–5. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Zhaojia Wang
    • 1
  • Panagiotis Korantzopoulos
    • 2
  • Tong Liu
    • 1
    Email author
  1. 1.Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of CardiologyThe Second Hospital of Tianjin Medical UniversityTianjinChina
  2. 2.First Department of Cardiology, Medical SchoolUniversity of IoanninaIoanninaGreece

Personalised recommendations